Model-Based Meta-Analysis (MBMA) Archives | Certara

Publication

A translational model-based meta-analysis to predict tremor incidence associated with serotonin reuptake transporter inhibition

The serotonin reuptake transporter (SERT) is responsible for the removal and recycling of the neurotransmitter…

Danielle PillsburyApril 30, 2025

On-Demand Webinar

Model-Based Meta-Analysis (MBMA) for Relative Treatment Effects and Absolute Outcomes: A Focus on Concepts and Applications

Vice President, MBMA Capability Lead, Certara Drug Development Solutions Matt advances the integration of published…

Danielle PillsburyApril 10, 2025

Webinar

Model-Based Meta-Analysis for All Phases of Drug Development: Capturing the Full Potential of Published Clinical Trial Outcomes [APAC Webinar]

May 29, 2025 - 10am Japan/Korea, 9am in China

Danielle PillsburyApril 3, 2025

Fact Sheet

Pharmacometrics Drug Development Decision Support: Model-Based Meta-Analysis (MBMA)

Danielle PillsburyFebruary 19, 2025

On-Demand Webinar

Solving Drug Development Challenges with Model-Based Meta-Analysis (MBMA)

In this on-demand webinar, "MBMA: Optimizing Drug Development with Aggregate Clinical Trial Data and Predictive…

Danielle PillsburyJanuary 9, 2025

Publication

INTERCEPT-AD, a phase 1 study of intravenous sabirnetug in participants with mild cognitive impairment or mild dementia due to Alzheimer’s disease

The Phase 1 INTERCEPT-AD study evaluated sabirnetug (ACU193), a monoclonal antibody targeting amyloid-beta oligomers (AβOs),…

Danielle PillsburyJanuary 8, 2025

Poster

Preclinical data exposures underpredict clinical physiologically active doses for bispecific T-cell engagers in solid tumors indications; are there better metrics? -insights from a small mechanistic MBMA

Danielle PillsburyDecember 11, 2024

Amgen

Case Study

Using MBMA to run virtual “head-to-head trials”

Osteoporosis is common in post-menopausal women. The long-term sequelae of osteoporosis include bone fractures, particularly…

Danielle PillsburyApril 21, 2023

Blog

A Bird’s Eye View on Rare Diseases: Key Drug Development Considerations for Thyroid Eye Disease

New therapeutics discovery and development for ocular diseases have been traditionally associated with a low…

CertaraDecember 15, 2021

Blog

Using Model-based Meta-analysis to Inform Neuropathic Pain Drug Development

Model-based Meta-analysis is a framework to compare drugs used to treat diabetic peripheral neuropathy, post-herpetic…

CertaraDecember 19, 2019

© 2025 Certara. All Rights Reserved. | Privacy policy